• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
ReportsnReports.com - Global Clinical Trials Market (2007 - 2010)
 

ReportsnReports.com - Global Clinical Trials Market (2007 - 2010)

on

  • 690 views

The global clinical trials conducted in 2008 were reported to be 10,326 and were highest from 2007 to 2010. Oncology trials were the most widely conducted clinical trials accounting for 28.47% of all ...

The global clinical trials conducted in 2008 were reported to be 10,326 and were highest from 2007 to 2010. Oncology trials were the most widely conducted clinical trials accounting for 28.47% of all the trials conducted for the year 2008. Asia reported to a steady growth as compared to the other regions; which showed decline in the total number of clinical trials in the year 2010.

Statistics

Views

Total Views
690
Views on SlideShare
690
Embed Views
0

Actions

Likes
0
Downloads
13
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    ReportsnReports.com - Global Clinical Trials Market (2007 - 2010) ReportsnReports.com - Global Clinical Trials Market (2007 - 2010) Document Transcript

    • Global Clinical Trials Market (2007 - 2010)Published: September 2011Price: $ 4650Clinical trials market now witnesses a paradigm shift. Naïve heterogeneous patientpopulations in the developing nations are opening up new avenues for the clinical trialsmarket. Developing countries also offer faster means; which is triggering majorpharmaceutical companies to direct their investment in these regions. Apart from this,stringent regulations and tight R&D budgets in the pharma-biotech industry are alsoforcing companies to move to east. This scenario has further boosted the alliancesbetween the pharma-biotech companies and the clinical research organizations, with thelatter accounting for major chunk of the trials conducted.Today, emerging countries account for the largest share of the phase II/III (prime stages)clinical trials conducted globally with major focus on oncology, Alzheimer’s, metabolic, andcardiovascular diseases. Support from the respective government bodies is one of themajor factors affecting the clinical trials market. Clinical trials sponsored by the industryhave a much higher share in the market as compared to government organizations.Browse All: Pharmaceuticals Market ResearchNorth America includes the U.S. and Canada; together both the countries have reported tohave the largest number of clinical trials conducted globally. In the European region,Germany heads the largest number of clinical trials, the country was reported to haveconducted 734 trials for 2010 in Western Europe while Poland accounted for the largestnumber of clinical trials in Eastern Europe with total number of 263 clinical trials for 2010.Asia is one of the fastest growing markets for global clinical trials. The countries taking leadin this market are India, China, South Korea, and Singapore. The major reasons for thismarket to have high potential are its huge and diverse population with diseases that arepresent in both - the developed and under developed countries. Hence, different types oftrials can be conducted in one region. Due to large population, it helps in faster recruitmentof the patients, and retention of the participants in the trials on the higher side; therebyhelping the companies to conduct the trials on the timely basis.The financial targets and global competition are forcing the pharmaceutical players to lookout for various options to introduce novel therapies in the market. At the same time,emerging shortage of clinical resources such as lack of naïve disease population, welltrained labor, and sound medical infrastructure are delaying the process to initiate trials.Hence, all these companies are considering Latin America as an alternative option forconducting clinical trials.
    • The key players (Clinical Research Organizations) in the market include Chiltern, Omnicare,PPD, Parexel, Kendle, and Quintles.The global clinical trials conducted in 2008 were reported to be 10,326 and were highestfrom 2007 to 2010. Oncology trials were the most widely conducted clinical trialsaccounting for 28.47% of all the trials conducted for the year 2008. Asia reported to asteady growth as compared to the other regions; which showed decline in the total numberof clinical trials in the year 2010.Scope of the reportGlobal clinical trials market research report categorizes by phases, by the study design, bythe disease indications and with analysis of the geographic trends of conducting the clinicaltrials.Clinical trials market by phases: Phase I Phase II Phase IIIClinical trials market by study design Interventional trials Observational trials Expanded Access trials.Clinical trials market by indications Autoimmune Blood disorders Cancer Circulatory CNS Congenital CVS Dermatology Ear Gastrointestinal Genitourinary Infections Mental disorders
    •  Metabolic Musculoskeletal Nose Ophthalmology OthersClinical trials on basis of geography: North America South America Asia EuropeEach section of the report provides market tables for covering the number of clinical trialsconducted between 2007 and 2010.In addition, the report also provides 19 company profiles of the CROs covering the servicesand geographic presence.TABLE OF CONTENTS1 INTRODUCTION1.1 KEY TAKE-AWAYS1.2 REPORT DESCRIPTION1.3 MARKETS COVERED1.4 STAKEHOLDERS1.5 RESEARCH METHODOLOGY2 EXECUTIVE SUMMARY2.1 OVERVIEW OF THE MARKET2.2 KEY FINDINGS3 MARKET OVERVIEW3.1 MARKET DEFINITION3.2 DRIVERS3.2.1 GLOBALIZING DRUG DEVELOPMENT ACTIVITIES3.2.2 RISE IN R&D INVESTMENTS EXPECTED TO BOOST THE CLINICAL TRIALS MARKET3.2.3 HIGH DISEASE PREVALENCE IN EMERGING COUNTRIES3.3 RESTRAINTS3.3.1 LONGER APPROVAL TIME FOR CLINICAL TRIALS – A CAUSE OF CONCERN FOR MAJORPHARMACEUTICAL-BIOTECHNOLOGY PLAYERS3.4 BURNING ISSUES3.4.1 OUT SKIRTING BOUNDARIES OF MEDICAL ETHICS3.5 WINNING IMPERATIVES3.5.1 LEVERAGING ONLINE RESOURCES TO INCREASE PATIENT RECRUITMENT RATES INCLINICAL TRIALS3.6 COUNTRY COMPARISON
    • 3.7 INDUSTRY TRENDS3.7.1 ENGAGING CLINICAL TRIALS IN EMERGING COUNTRIES & LOW COST CRO’S PROVETO BE COMPELLING OPTIONS IN TIMES OF DRUG PATENT EXPIRY3.7.2 CROS LEVERAGING THE BENEFITS OF EMERGING MARKETS3.7.3 CHANGING CRO BUSINESS MODELS3.7.3.1 Full service model3.7.3.2 Hourly billing model3.7.3.3 Full time equivalent model (FTE)3.7.3.4 Fixed price model3.7.4 PREVALENCE OF PREFERRED PROVIDER RELATIONSHIPS3.7.5 SHIFT TOWARDS PATIENT CENTRIC CLINICAL TRIALS DUE TO TECHNICALADVANCES3.8 GLOBAL CLINICAL TRIALS MARKET3.8.1 OFFSHORING & OUTSOURCING4 CLINICAL TRIALS MARKET, BY TYPES4.1 INTRODUCTION4.1.1 CLINICAL TRIALS MARKET, BY STUDY PHASES4.1.1.1 Preclinical studies4.1.1.2 Phase I trials4.1.1.3 Phase II trials4.1.1.4 Phase I/II4.1.1.5 Phase II/III4.1.1.6 Phase III trials4.1.2 CLINICAL TRIALS MARKET, BY STUDY DESIGNS4.1.2.1 Observational studies4.1.2.2 Interventional studies4.1.2.3 Expanded Access Trials4.1.3 CLINICAL TRIALS MARKET, BY INDICATIONS5 GEOGRAPHIC ANALYSIS5.1 NORTH AMERICA5.1.1 U.S.5.1.1.1 Regulatory environment5.1.1.2 Clinical trials registry5.1.1.3 Government support5.1.2 CANADA5.1.2.1 Regulatory environment5.1.2.2 Clinical trials registry5.1.2.3 Government support5.2 EUROPE5.2.1 UK5.2.1.1 Regulatory environment5.2.1.2 Clinical trials registry5.2.1.3 Government support5.2.2 GERMANY5.2.2.1 Regulatory environment5.2.2.2 Clinical trials registry5.2.2.3 Government support5.2.3 ITALY
    • 5.2.3.1 Regulatory environment5.2.3.2 Clinical trials registry5.2.3.3 Government support5.2.4 FRANCE5.2.4.1 Regulatory environment5.2.4.2 Clinical trials registry5.2.4.3 Support rendered by the government5.2.5 SPAIN5.2.5.1 Regulatory environment5.2.5.2 Clinical trials registry5.2.5.3 Government support5.2.6 POLAND5.2.6.1 Regulatory environment5.2.6.2 Clinical trials registry5.2.6.3 Support rendered by the Government5.2.7 RUSSIA5.2.7.1 Regulatory environment5.2.7.2 Clinical trials registry5.2.7.3 Support rendered by the Government5.2.8 TURKEY5.2.8.1 Regulatory environment5.2.8.2 Clinical trials registry5.2.8.3 Government support5.2.9 UKRAINE5.2.9.1 Regulatory environment5.2.9.2 Clinical trials registry5.2.9.3 Support rendered by the Government5.3 ASIA5.3.1 CHINA5.3.1.1 Clinical trials registry5.3.1.2 Government support5.3.2 INDIA5.3.2.1 Regulatory environment5.3.2.2 Clinical trials registry5.3.2.3 Government support5.3.3 SOUTH KOREA5.3.3.1 Regulatory environment5.3.3.2 Clinical trials registry5.3.3.3 Government support5.4 LATIN AMERICA5.4.1 BRAZIL5.4.1.1 Regulatory environment5.4.1.2 Clinical trials registry5.4.1.3 Government support5.4.2 MEXICO5.4.2.1 Regulatory environment5.4.2.2 Clinical trials registry5.4.2.3 Government support5.4.3 ARGENTINA5.4.3.1 Regulatory environment
    • 5.4.3.2 Clinical trials registry5.4.3.3 Government support6 COMPETITIVE LANDSCAPE6.1 INTRODUCTION7 COMPANY PROFILES7.1 AAIPHARMA SERVICES CORP.7.1.1 OVERVIEW7.1.2 FINANCIALS7.1.3 PRODUCTS & SERVICES7.1.4 STRATEGY7.1.5 DEVELOPMENTS7.2 ACCELL CLINICAL RESEARCH LLC7.2.1 OVERVIEW7.2.2 FINANCIALS7.2.3 PRODUCTS & SERVICES7.2.4 STRATEGY7.2.5 DEVELOPMENTS7.3 APTIV SOLUTIONS7.3.1 OVERVIEW7.3.2 FINANCIALS7.3.3 PRODUCTS & SERVICES7.3.4 STRATEGY7.3.5 DEVELOPMENTS7.4 CHILTERN INTERNATIONAL LIMITED7.4.1 OVERVIEW7.4.2 FINANCIALS7.4.3 PRODUCTS & SERVICES7.4.4 STRATEGY7.4.5 DEVELOPMENTS7.5 CONGENIX7.5.1 OVERVIEW7.5.2 FINANCIALS7.5.3 PRODUCTS & SERVICES7.5.4 STRATEGY7.5.5 DEVELOPMENTS7.6 COVANCE INC.7.6.1 OVERVIEW7.6.2 FINANCIALS7.6.3 PRODUCTS & SERVICES7.6.4 STRATEGY7.6.5 DEVELOPMENTS7.7 ECRON ACUNOVA LTD7.7.1 OVERVIEW7.7.2 FINANCIALS7.7.3 PRODUCTS & SERVICES7.7.4 STRATEGY7.7.5 DEVELOPMENTS7.8 EUROTRIALS
    • 7.8.1 OVERVIEW7.8.2 FINANCIALS7.8.3 PRODUCTS & SERVICES7.8.4 DEVELOPMENTS7.9 ICON PLC7.9.1 OVERVIEW7.9.2 FINANCIALS7.9.3 PRODUCTS & SERVICES7.9.4 STRATEGY7.9.5 DEVELOPMENTS7.10 INC RESEARCH LLC7.10.1 OVERVIEW7.10.2 FINANCIALS7.10.3 PRODUCTS & SERVICES7.10.4 STRATEGY7.10.5 DEVELOPMENTS7.11 MEDPACE INC7.11.1 OVERVIEW7.11.2 FINANCIALS7.11.3 PRODUCTS & SERVICES7.11.4 STRATEGY7.11.5 DEVELOPMENTS7.12 PAREXEL INTERNATIONAL CORP7.12.1 OVERVIEW7.12.2 FINANCIALS7.12.3 PRODUCTS & SERVICES7.12.4 STRATEGY7.12.5 DEVELOPMENTS7.13 PHARMANET DEVELOPMENT GROUP7.13.1 OVERVIEW7.13.2 FINANCIALS7.13.3 PRODUCTS & SERVICES7.13.4 STRATEGY7.13.5 DEVELOPMENTS7.14 PHARMACEUTICAL PRODUCT DEVELOPMENT INC7.14.1 OVERVIEW7.14.2 FINANCIALS7.14.3 PRODUCTS & SERVICES7.14.4 STRATEGY7.14.5 DEVELOPMENTS7.15 PRA INTERNATIONAL7.15.1 OVERVIEW7.15.2 FINANCIALS7.15.3 PRODUCTS & SERVICES7.15.4 STRATEGY7.15.5 DEVELOPMENTS7.16 QUINTILES TRANSNATIONAL CORP7.16.1 OVERVIEW7.16.2 FINANCIALS7.16.3 PRODUCTS & SERVICES
    • 7.16.4 STRATEGY7.16.5 DEVELOPMENTS7.17 SIRO CLINPHARM PVT. LTD7.17.1 OVERVIEW7.17.2 FINANCIALS7.17.3 PRODUCTS & SERVICES7.17.4 STRATEGY7.17.5 DEVELOPMENTS7.18 TCG LIFESCIENCES LTD7.18.1 OVERVIEW7.18.2 FINANCIALS7.18.3 PRODUCTS & SERVICES7.18.4 STRATEGY7.18.5 DEVELOPMENTS7.19 THEOREM CLINICAL RESEARCH7.19.1 OVERVIEW7.19.2 FINANCIALS7.19.3 PRODUCTS & SERVICES7.19.4 STRATEGY7.19.5 DEVELOPMENTSLIST OFTABLESTABLE 1GLOBAL CLINICAL TRIALS, BY PHASES, 2007 – 2010 (NO. OF TRIALS)TABLE 2CLINICAL TRIALS APPROVAL: TIME & AUTHORITYTABLE 3DRUGS SET FOR PATENT EXPIRATIONS, 2010–2012TABLE 4PHASE I CLINICAL TRIALS MARKET, BY GEOGRAPHY, 2007 – 2010 (NO. OF TRIALS)TABLE 5GLOBAL PHASE I CLINICAL TRIALS MARKET, BY INDICATIONS, 2007 – 2010 (NO.OF TRIALS)TABLE 6PHASE II CLINICAL TRIALS MARKET, BY GEOGRAPHY, 2007 – 2010 (NO. OFTRIALS)TABLE 7GLOBAL PHASE II CLINICAL TRIALS MARKET, BY INDICATIONS, 2007 – 2010 (NO.OF TRIALS)TABLE 8PHASE I/II CLINICAL TRIALS MARKET, BY GEOGRAPHY, 2007 – 2010 (NO. OFTRIALS)TABLE 9GLOBAL PHASE I/II CLINICAL TRIALS, BY INDICATIONS, 2007 – 2010 (NO. OFTRIALS)TABLE 10 PHASE II/III CLINICAL TRIALS MARKET, BY GEOGRAPHY, 2007 – 2010 (NO. OFTRIALS)TABLE 11 GLOBAL PHASE II/III CLINICAL TRIALS MARKET, BY INDICATIONS, 2007 – 2010(NO. OF TRIALS)TABLE 12 PHASE III CLINICAL TRIALS MARKET, BY GEOGRAPHY, 2007 – 2010 (NO. OFTRIALS)TABLE 13 GLOBAL PHASE III CLINICAL TRIALS MARKET, BY INDICATIONS, 2007 – 2010(NO. OF TRIALS)TABLE 14 OBSERVATIONAL STUDIES: CLINICAL TRIALS MARKET, BY GEOGRAPHY, 2007 –2010 (NO. OF TRIALS)TABLE 15 INTERVENTIONAL STUDIES: CLINICAL TRIALS MARKET, BY GEOGRAPHY, 2007 –2010 (NO. OF TRIALS)TABLE 16 EXPANDED ACCESS: CLINICAL TRIALS, BY GEOGRAPHY, 2007 – 2010 (NO. OF
    • TRIALS)TABLE 17 GLOBAL CLINICAL TRIALS MARKET, BY INDICATIONS, 2007 – 2010 (NO. OFTRIALS)TABLE 18 NORTH AMERICA: CLINICAL TRIALS MARKET, BY COUNTRIES, 2007 – 2010 (NO.OF TRIALS)TABLE 19 U.S: CLINICAL TRIALS MARKET, BY PHASES, 2007 – 2010 (NO. OF TRIALS)TABLE 20 U.S: CLINICAL TRIALS MARKET, BY STUDY DESIGNS, 2007 – 2010 (NO. OFTRIALS)TABLE 21 U.S: CLINICAL TRIALS MARKET, BY INDICATIONS, 2007 – 2010 (NO. OF TRIALS)TABLE 22 CANCER FUNDING IN THE U.S., BY TYPES, 2008 – 2010 ($MILLION)TABLE 23 CANADA: CLINICAL TRIALS MARKET, BY PHASES, 2007 – 2010 (NO. OF TRIALS)TABLE 24 CANADA: CLINICAL TRIALS MARKET, BY STUDY DESIGNS, 2007 – 2010 (NO. OFTRIALS)TABLE 25 CANADA: CLINICAL TRIALS MARKET, BY INDICATIONS, 2007 – 2010 (NO. OFTRIALS)TABLE 26 EUROPE: CLINICAL TRIALS MARKET, BY COUNTRIES, 2007 – 2010 (NO. OFTRIALS)TABLE 27 UK: CLINICAL TRIALS MARKET, BY PHASES, 2007 – 2010 (NO. OF TRIALS)TABLE 28 UK: CLINICAL TRIALS MARKET, BY STUDY DESIGNS, 2007 – 2010 (NO. OFTRIALS)TABLE 29 UK: CLINICAL TRIALS MARKET, BY INDICATIONS, 2007 – 2010 (NO. OF TRIALS)TABLE 30 GERMANY: CLINICAL TRIALS MARKET, BY PHASES, 2007 – 2010 (NO. OF TRIALS)TABLE 31 GERMANY: CLINICAL TRIALS MARKET, BY STUDY DESIGNS, 2007 – 2010 (NO. OFTRIALS)TABLE 32 GERMANY: CLINICAL TRIALS MARKET, BY INDICATIONS, 2007 – 2010 (NO. OFTRIALS)TABLE 33 ITALY: CLINICAL TRIALS MARKET, BY PHASES, 2007 – 2010 (NO. OF TRIALS)TABLE 34 ITALY: CLINICAL TRIALS MARKET, BY STUDY DESIGNS, 2007 – 2010 (NO. OFTRIALS)TABLE 35 ITALY: CLINICAL TRIALS MARKET, BY INDICATIONS, 2007 – 2010 (NO. OFTRIALS)TABLE 36 FRANCE: CLINICAL TRIALS MARKET, BY PHASES, 2007 – 2010 (NO. OF TRIALS)TABLE 37 FRANCE: CLINICAL TRIALS MARKET, BY STUDY DESIGNS, 2007 – 2010 (NO. OFTRIALS)TABLE 38 FRANCE: CLINICAL TRIALS MARKET, BY INDICATIONS, 2007 – 2010 (NO. OFTRIALS)TABLE 39 SPAIN: CLINICAL TRIALS MARKET, BY PHASES, 2007 – 2010 (NO. OF TRIALS)TABLE 40 SPAIN: CLINICAL TRIALS MARKET, BY STUDY DESIGNS, 2007 – 2010 (NO. OFTRIALS)TABLE 41 SPAIN: CLINICAL TRIALS MARKET, BY INDICATIONS, 2007 – 2010 (NO. OFTRIALS)TABLE 42 POLAND: CLINICAL TRIALS MARKET, BY PHASES, 2007 – 2010 (NO. OF TRIALS)TABLE 43 POLAND: CLINICAL TRIALS MARKET, BY PHASES, 2007 – 2010 (NO. OF TRIALS)TABLE 44 POLAND: CLINICAL TRIALS MARKET, BY INDICATIONS, 2007 – 2010 (NO. OFTRIALS)TABLE 45 RUSSIA: CLINICAL TRIALS MARKET BY PHASES, 2007 – 2010 (NO. OF TRIALS)TABLE 46 RUSSIA: CLINICAL TRIALS MARKET, BY STUDY DESIGNS, 2007 – 2010 (NO. OFTRIALS)TABLE 47 RUSSIA: CLINICAL TRIALS MARKET, BY INDICATIONS, 2007 – 2010 (NO. OFTRIALS)
    • TABLE 48 TURKEY: CLINICAL TRIALS MARKET, BY PHASES, 2007 – 2010 (NO. OF TRIALS)TABLE 49 TURKEY: CLINICAL TRIALS MARKET, BY STUDY DESIGNS, 2007 – 2010 (NO. OFTRIALS)TABLE 50 TURKEY: CLINICAL TRIALS MARKET, BY INDICATIONS, 2007 – 2010 (NO. OFTRIALS)TABLE 51 UKRAINE: CLINICAL TRIALS MARKET, BY PHASES, 2007 – 2010 (NO. OF TRIALS)TABLE 52 UKRAINE: CLINICAL TRIALS MARKET, BY STUDY DESIGNS, 2007 – 2010 (NO. OFTRIALS)TABLE 53 UKRAINE: CLINICAL TRIALS MARKET, BY INDICATIONS, 2007 – 2010 (NO. OFTRIALS)TABLE 54 ASIA: CLINICAL TRIALS MARKET, BY COUNTRY, 2007 – 2010 (NO. OF TRIALS)TABLE 55 CHINA: CLINICAL TRIALS MARKET, BY PHASES, 2007 – 2010 (NO. OF TRIALS)TABLE 56 CHINA: CLINICAL TRIALS MARKET, BY STUDY DESIGNS, 2007 – 2010 (NO. OFTRIALS)TABLE 57 CHINA: CLINICAL TRIALS MARKET, BY INDICATIONS, 2007 – 2010 (NO. OFTRIALS)TABLE 58 INDIA: CLINICAL TRIALS MARKET, BY PHASES, 2007 – 2010 (NO. OF TRIALS)TABLE 59 INDIA: CLINICAL TRIALS MARKET, BY STUDY DESIGNS, 2007 – 2010 (NO. OFTRIALS)TABLE 60 INDIA: CLINICAL TRIALS MARKET, BY INDICATIONS, 2007 – 2010 (NO. OFTRIALS)TABLE 61 SOUTH KOREA: CLINICAL TRIALS MARKET, BY PHASES, 2007 – 2010 (NO. OFTRIALS)TABLE 62 SOUTH KOREA: CLINICAL TRIALS MARKET, BY STUDY DESIGNS, 2007 – 2010(NO. OF TRIALS)TABLE 63 SOUTH KOREA: CLINICAL TRIALS MARKET, BY INDICATIONS, 2007 – 2010 (NO.OF TRIALS)TABLE 64 LATIN AMERICA: CLINICAL TRIALS MARKET, BY COUNTRY, 2007 – 2010 (NO. OFTRIALS)TABLE 65 BRAZIL: CLINICAL TRIALS MARKET, BY PHASES, 2007 – 2010 (NO. OF TRIALS)TABLE 66 BRAZIL: CLINICAL TRIALS MARKET, BY STUDY DESIGNS, 2007 – 2010 (NO. OFTRIALS)TABLE 67 BRAZIL: CLINICAL TRIALS MARKET, BY INDICATIONS, 2007 – 2010 (NO. OFTRIALS)TABLE 68 MEXICO: CLINICAL TRIALS MARKET, BY PHASES, 2007 – 2010 (NO. OF TRIALS)TABLE 69 MEXICO: CLINICAL TRIALS MARKET, BY STUDY DESIGNS, 2007 – 2010 (NO. OFTRIALS)TABLE 70 MEXICO: CLINICAL TRIALS MARKET, BY INDICATIONS, 2007 – 2010 (NO. OFTRIALS)TABLE 71 ARGENTINA: CLINICAL TRIALS MARKET, BY PHASES, 2007 – 2010 (NO. OFTRIALS)TABLE 72 ARGENTINA: CLINICAL TRIALS MARKET, BY STUDY DESIGNS, 2007 – 2010 (NO.OF TRIALS)TABLE 73 ARGENTINA: CLINICAL TRIALS MARKET, BY INDICATIONS, 2007 – 2010 (NO. OFTRIALS)TABLE 74 NEW APPROVALS, 2008 – 2010TABLE 75 EXPANSIONS, 2008 – 2011TABLE 76 NEW TRIALS, 2007 – 2011TABLE 77 COLLABORATIONS & PARTNERSHIPS, 2008 – 2011TABLE 78 MERGERS & ACQUISITIONS, 2007 – 2011
    • TABLE 79 CHILTERN: TOTAL REVENUE, 2008 – 2010 ($MILLION)TABLE 80 COVANCE INC: TOTAL REVENUE, 2008 – 2010 ($MILLION)TABLE 81 COVANCE INC.: TOTAL REVENUE, BY COUNTRY, 2008 – 2010 ($MILLION)TABLE 82 COVANCE INC: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)TABLE 83 ICON PLC: TOTAL REVENUE, 2008 – 2010 ($MILLION)TABLE 84 ICON PLC: TOTAL REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)TABLE 85 ICON PLC: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)TABLE 86 PAREXEL INTERNATIONAL CORPORATION: TOTAL REVENUE, BY GEOGRAPHY,2008 – 2010 ($MILLION)TABLE 87 PAREXEL INTERNATIONAL CORPORATION: TOTAL REVENUE, BY SEGMENTS, 2008– 2010 ($MILLION)TABLE 88 PHARMACEUTICAL PRODUCT DEVELOPMENT INC: TOTAL REVENUE, 2008 – 2010($MILLION)TABLE 89 PHARMACEUTICAL PRODUCT DEVELOPMENT INC: TOTAL REVENUE, BY COUNTRY,2008 – 2010 ($MILLION)TABLE 90 PHARMACEUTICAL PRODUCT DEVELOPMENT INC: TOTAL REVENUE, BYSEGMENTS, 2008 – 2010 ($MILLION)TABLE 91 THEOREM CLINICAL RESEARCH: TOTAL REVENUE, 2008 – 2010 ($MILLION)TABLE 92 THEOREM CLINICAL RESEARCH: TOTAL REVENUE, BY COUNTRY, 2008 – 2010($MILLION)TABLE 93 THEOREM CLINICAL RESEARCH: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010($MILLION)LIST OFFIGURESFIGURE 1COUNTRY WISE PARAMETRIC COMPARISONFIGURE 2COST OF CLINICAL TRIALS, BY COUNTRYFIGURE 3U.S: CLINICAL TRIALS REGULATORY PROCESSFIGURE 4CANADA: CLINICAL TRIALS REGULATORY PROCESSFIGURE 5UK: CLINICAL TRIALS REGULATORY PROCESSFIGURE 6GERMANY: CLINICAL TRIALS REGULATORY PROCESSFIGURE 7ITALY: CLINICAL TRIALS REGULATORY PROCESSFIGURE 8FRANCE: CLINICAL TRIALS REGULATORY PROCESSFIGURE 9SPAIN: CLINICAL TRIALS REGULATORY PROCESSFIGURE 10 POLAND: CLINICAL TRIALS REGULATORY PROCESSFIGURE 11 RUSSIA: CLINICAL TRIALS REGULATORY PROCESSFIGURE 12 TURKEY: CLINICAL TRIALS REGULATORY PROCESSFIGURE 13 UKRAINE: CLINICAL TRIALS REGULATORY PROCESSFIGURE 14 CHINA: CLINICAL TRIALS REGULATORY PROCESSFIGURE 15 INDIA: CLINICAL TRIALS REGULATORY PROCESSFIGURE 16 SOUTH KOREA: CLINICAL TRIALS REGULATORY PROCESSFIGURE 17 BRAZIL: CLINICAL TRIALS REGULATORY PROCESSFIGURE 18 MEXICO: CLINICAL TRIALS REGULATORY PROCESSFIGURE 19 ARGENTINA: CLINICAL TRIALS REGULATORY PROCESSFIGURE 20 MAJOR GROWTH STRATEGIES IN GLOBAL CLINICAL TRIALS MARKET, JANUARY2008 – JULY 2011About Us:
    • ReportsnReports is an online library of over 100,000+ market research reports and in-depthmarket research studies & analysis of over 5000 micro markets. We provide 24/7 online andoffline support to our customers. Get in touch with us for your needs of market researchreports.Follow us on Twitter: http://twitter.com/marketsreportsOur Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689Contact:Mr.Priyank7557 Rambler road,Suite727,Dallas,TX75231Tel: + 1 888 391 5441E-mail: sales@reportsandreports.comhttp://www.reportsnreports.comVisit our Market Research Blog